CH Biotech R&D Co (TPE:6534) Notes Receivable: NT$0 Mil (As of Dec. 2025)


TPE:6534 CH Biotech R&D Co Ltd TPE:6534
84 GF Score
Price NT$90.20
GF Value NT$100.55
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is CH Biotech R&D Co Notes Receivable?

CH Biotech R&D Co TPE:6534 +0.11% 84 Notes Receivable is NT$0 Mil as of Dec. 2025. GuruFocus rates TPE:6534 with a GF Score™ of 84/100 and a GF Value™ of NT$100.55 (Modestly Undervalued). The stock has 1 warning sign investors should review.

CH Biotech R&D Co's Notes Receivable for the quarter that ended in Dec. 2025 was NT$0 Mil.

CH Biotech R&D Co Notes Receivable Related Terms

CH Biotech R&D Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for CH Biotech R&D Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CH Biotech R&D Co Notes Receivable Chart

CH Biotech R&D Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CH Biotech R&D Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6534
84GF Score
CH Biotech R&D Co Ltd TPE:6534
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CH Biotech R&D Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of NT$0 Mil mean?
CH Biotech R&D Co (TPE:6534) has a Notes Receivable of NT$0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CH Biotech R&D Co and its competitors.
Is CH Biotech R&D Co's Notes Receivable too high?
CH Biotech R&D Co's current Notes Receivable is NT$0 Mil. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Notes Receivable compare to CTVA and CF?
CH Biotech R&D Co's Notes Receivable of NT$0 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for an Agriculture company?
A good Notes Receivable depends on the Agriculture industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CH Biotech R&D Co and its competitors. CH Biotech R&D Co's current Notes Receivable is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$100.55, compared to a current price of NT$90.20 — trading 10.3% below its estimated fair value. The current Notes Receivable is NT$0 Mil. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Notes Receivable is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?

Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued. The current stock price of NT$90.20 is trading 10.3% below its estimated GF Value™ of NT$100.55. GuruFocus considers CH Biotech R&D Co to be Modestly Undervalued.

Key valuation signals for TPE:6534:

  • Notes Receivable: NT$0 Mil
  • GF Value™: NT$100.55 vs. price of NT$90.20 (10.3% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CH Biotech R&D Co Business Description

Address No. 89, Wenxian Road, Nantou County, Nantou City, TWN, 540001
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score

Get the complete analysis for TPE:6534

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$90.20
Price
NT$100.55
GF Value